Forskning ved Københavns Universitet - Københavns Universitet

Forside

Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. / Alberdi-Saugstrup, Mikel; Nielsen, Susan; Mathiessen, Pernille; Nielsen, Claus Henrik; Müller, Klaus.

I: Clinical Rheumatology, Bind 36, Nr. 1, 2017, s. 67-75.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Alberdi-Saugstrup, M, Nielsen, S, Mathiessen, P, Nielsen, CH & Müller, K 2017, 'Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis', Clinical Rheumatology, bind 36, nr. 1, s. 67-75. https://doi.org/10.1007/s10067-016-3375-x

APA

Alberdi-Saugstrup, M., Nielsen, S., Mathiessen, P., Nielsen, C. H., & Müller, K. (2017). Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clinical Rheumatology, 36(1), 67-75. https://doi.org/10.1007/s10067-016-3375-x

Vancouver

Alberdi-Saugstrup M, Nielsen S, Mathiessen P, Nielsen CH, Müller K. Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clinical Rheumatology. 2017;36(1):67-75. https://doi.org/10.1007/s10067-016-3375-x

Author

Alberdi-Saugstrup, Mikel ; Nielsen, Susan ; Mathiessen, Pernille ; Nielsen, Claus Henrik ; Müller, Klaus. / Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. I: Clinical Rheumatology. 2017 ; Bind 36, Nr. 1. s. 67-75.

Bibtex

@article{24db48412da34a86b1ffdf78d5759cdb,
title = "Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis",
abstract = "Two thirds of patients with juvenile idiopathic arthritis (JIA) treated with tumor necrosis factor (TNF)-alpha inhibitors respond initially, but only about one third of patients achieve clinical remission at follow-up. We evaluated the 1-year response and long-term treatment adherence to TNF inhibitor treatment in JIA patients naive to biologics and investigated if baseline myeloid-related protein (MRP)-8/14 and C-reactive protein (CRP) were predictive of treatment response. One hundred fifty-two patients were included in a unicenter observational, prospective study from 2002 to 2015, excluding patients with systemic-onset JIA. One-year treatment response was evaluated by American College of Rheumatology-pediatric (ACR-ped) and by the number of patients achieving inactive disease (ID). Medical charts were reviewed for reasons of treatment withdrawal. After one year of treatment ACR-ped 30, 50, 70, and 90 were achieved by 61, 55, 38, and 10 {\%} of the patients, and 23 {\%} achieved a status of ID. Treatment adherence: 51 {\%} withdrew from treatment due to lack of clinical effect, while 32 {\%} continued treatment or withdrew due to disease remission. Increased MRP-8/14 concentrations at treatment initiation was associated with ID after 1 year (OR 1.55, CI 1.06–2.25, p = 0.02). Treatment withdrawal due to lack of effect was associated with low baseline levels of both MRP-8/14 (685 vs. 1235 ng/ml, p < 0.001) and CRP (0.75 vs. 2.73 mg/l, p < 0.001), verified by multivariable logistic regression analysis (OR 0.51, CI 0.34–0.77/OR 0.63, CI 0.48–0.83). In conclusion, an association was found between ID after 1 year of treatment and increased baseline levels of MRP-8/14. Furthermore, low baseline MRP-8/14 and CRP concentrations were associated with treatment withdrawal due to lack of clinical effect.",
keywords = "Biomarkers < methodology, Clinical trials < methodology, High-sensitivity CRP, Juvenile idiopathic arthritis < rheumatic diseases, Myeloid-related protein, TNF inhibitor",
author = "Mikel Alberdi-Saugstrup and Susan Nielsen and Pernille Mathiessen and Nielsen, {Claus Henrik} and Klaus M{\"u}ller",
year = "2017",
doi = "10.1007/s10067-016-3375-x",
language = "English",
volume = "36",
pages = "67--75",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis

AU - Alberdi-Saugstrup, Mikel

AU - Nielsen, Susan

AU - Mathiessen, Pernille

AU - Nielsen, Claus Henrik

AU - Müller, Klaus

PY - 2017

Y1 - 2017

N2 - Two thirds of patients with juvenile idiopathic arthritis (JIA) treated with tumor necrosis factor (TNF)-alpha inhibitors respond initially, but only about one third of patients achieve clinical remission at follow-up. We evaluated the 1-year response and long-term treatment adherence to TNF inhibitor treatment in JIA patients naive to biologics and investigated if baseline myeloid-related protein (MRP)-8/14 and C-reactive protein (CRP) were predictive of treatment response. One hundred fifty-two patients were included in a unicenter observational, prospective study from 2002 to 2015, excluding patients with systemic-onset JIA. One-year treatment response was evaluated by American College of Rheumatology-pediatric (ACR-ped) and by the number of patients achieving inactive disease (ID). Medical charts were reviewed for reasons of treatment withdrawal. After one year of treatment ACR-ped 30, 50, 70, and 90 were achieved by 61, 55, 38, and 10 % of the patients, and 23 % achieved a status of ID. Treatment adherence: 51 % withdrew from treatment due to lack of clinical effect, while 32 % continued treatment or withdrew due to disease remission. Increased MRP-8/14 concentrations at treatment initiation was associated with ID after 1 year (OR 1.55, CI 1.06–2.25, p = 0.02). Treatment withdrawal due to lack of effect was associated with low baseline levels of both MRP-8/14 (685 vs. 1235 ng/ml, p < 0.001) and CRP (0.75 vs. 2.73 mg/l, p < 0.001), verified by multivariable logistic regression analysis (OR 0.51, CI 0.34–0.77/OR 0.63, CI 0.48–0.83). In conclusion, an association was found between ID after 1 year of treatment and increased baseline levels of MRP-8/14. Furthermore, low baseline MRP-8/14 and CRP concentrations were associated with treatment withdrawal due to lack of clinical effect.

AB - Two thirds of patients with juvenile idiopathic arthritis (JIA) treated with tumor necrosis factor (TNF)-alpha inhibitors respond initially, but only about one third of patients achieve clinical remission at follow-up. We evaluated the 1-year response and long-term treatment adherence to TNF inhibitor treatment in JIA patients naive to biologics and investigated if baseline myeloid-related protein (MRP)-8/14 and C-reactive protein (CRP) were predictive of treatment response. One hundred fifty-two patients were included in a unicenter observational, prospective study from 2002 to 2015, excluding patients with systemic-onset JIA. One-year treatment response was evaluated by American College of Rheumatology-pediatric (ACR-ped) and by the number of patients achieving inactive disease (ID). Medical charts were reviewed for reasons of treatment withdrawal. After one year of treatment ACR-ped 30, 50, 70, and 90 were achieved by 61, 55, 38, and 10 % of the patients, and 23 % achieved a status of ID. Treatment adherence: 51 % withdrew from treatment due to lack of clinical effect, while 32 % continued treatment or withdrew due to disease remission. Increased MRP-8/14 concentrations at treatment initiation was associated with ID after 1 year (OR 1.55, CI 1.06–2.25, p = 0.02). Treatment withdrawal due to lack of effect was associated with low baseline levels of both MRP-8/14 (685 vs. 1235 ng/ml, p < 0.001) and CRP (0.75 vs. 2.73 mg/l, p < 0.001), verified by multivariable logistic regression analysis (OR 0.51, CI 0.34–0.77/OR 0.63, CI 0.48–0.83). In conclusion, an association was found between ID after 1 year of treatment and increased baseline levels of MRP-8/14. Furthermore, low baseline MRP-8/14 and CRP concentrations were associated with treatment withdrawal due to lack of clinical effect.

KW - Biomarkers < methodology

KW - Clinical trials < methodology

KW - High-sensitivity CRP

KW - Juvenile idiopathic arthritis < rheumatic diseases

KW - Myeloid-related protein

KW - TNF inhibitor

U2 - 10.1007/s10067-016-3375-x

DO - 10.1007/s10067-016-3375-x

M3 - Journal article

C2 - 27562034

AN - SCOPUS:84983460694

VL - 36

SP - 67

EP - 75

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 1

ER -

ID: 188489888